REAGENTS FOR DRUG TOXICITY STUDIES USING MEGAKARYOCYTES

描述：造血细胞定义的无蛋白的研究进展 支持巨核细胞形成的试剂将是不可估量的 重要性。开发这种试剂的理由是它将 允许在非结合状态下测量药物毒性，在该状态下所有 药物的一部分是有效的。这种试剂的优点是它们将 为此类检测提供统一的标准试剂，节省研究人员的时间 和努力开发这类试剂并促进药物评价 不含成键药物。这项建议结合了两种方法的优点 实验室，擅长开发无蛋白和无血清 另一种用于巨核细胞检测。这样的组合 这对这项提议的成功来说应该是个好兆头。第一阶段的工作 将专注于为一只小鼠开发确定的试剂 巨核细胞分析，并在时间允许的情况下，在第二阶段的努力中 用于人类巨核细胞分析的限定试剂的发展。

DESCRIPTION: The development of hematopoietic defined protein-free reagents that support megakaryocyte formation will be of inestimatable importance. The rationale for developing such reagents is that it will allow the measurement of drug toxicity in its unbound state in which all of the drug is active. The advantages to such reagents are they will be uniform standard reagents for such assays, save investigator time and effort in developing such reagents and facilitate drug evaluation free of bond drug. This proposal combines the strengths of two laboratories, one skilled in development of protein-free and serum-free reagents and the other in megakaryocyte assay. Such a combination should bode well for the success of this proposal. The Phase I effort will focus on the development of defined reagents for a murine megakaryocyte assays and, as time permits, and in the Phase II effort the development of defined reagants for human megakaryocyte assays.